Industry Alliance for Microphysiological Systems

What Industry Alliance for Microphysiological Systems does

Industry Alliance for Microphysiological Systems (IAMPS) is a Brussels-headquartered, member-funded non-profit industry association announced on 10 February 2026 and targeted to become operational in Q2 2026. It is described as the world's first industry association dedicated to representing European microphysiological systems (MPS) providers, and it unites nine founding member companies headquartered across Switzerland, Italy, the Netherlands, Germany, and France: AlveoliX, BiomimX, Chiron, Dynamic42, InSphero, MIMETAS, NETRI, React4Life, and TissUse. Each member brings a specialized organ-on-chip or 3D in vitro platform spanning barrier models, beating organ systems, multi-organ chips, electrophysiology, and 3D spheroid/organoid assays for drug safety, efficacy, ADME, and toxicology applications.

IAMPS's core function is to serve as a unified industry voice in three strategic pillars: industrial alignment, regulatory interface, and European sovereignty. It coordinates engagement with international regulators — specifically the FDA, PMDA, MHRA, and EMA — on validation, standardisation, and methodology evaluation to accelerate the regulatory acceptance of MPS-derived data as credible alternatives to animal models under the New Approach Methodologies (NAMs) framework. The association advocates at the European level for strategic autonomy, balanced industry representation, and long-term infrastructures that position MPS as a strategic European technology.

Revenue mechanics are membership-based, with specific pricing tiers not publicly disclosed. There are no reported funding rounds, institutional investors, parent companies, or subsidiaries. Governance is exercised through a Board of Directors with one representative per founding company, alongside an executive team comprising a President (Thibault Honegger, NETRI) and two Vice Presidents (Paola Occhetta, BiomimX; Jos Joore, MIMETAS). End-user segments include pharmaceutical and biotech companies using MPS for preclinical drug evaluation, regulatory authorities engaging on NAMs acceptance, and academic/research institutions involved in MPS validation and training.

Name

Industry Alliance for Microphysiological Systems

Legal name

Industry Alliance for Microphysiological Systems

Website

https://iamps.eu

Company type

Private

Founded year

2026

Operating status

Operating

Headcount range

11–50 employees

Short description

IAMPS is the world's first industry association representing European microphysiological systems providers, uniting nine founding member companies to coordinate regulatory engagement with the FDA, PMDA, MHRA, and EMA on MPS technology standardisation, validation, and adoption.

Ownership category

akta.pro rank

Headquarters

HQ city

Brussels

HQ country

Belgium

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Core offering

IAMPS is a non-profit industry association uniting nine European microphysiological systems (MPS) providers under a single industry voice. It provides coordinated regulatory engagement with the FDA, PMDA, MHRA, and EMA, advances device standardization, and structures the European MPS market through three strategic pillars: Industrial Alignment, Regulatory Interface, and European Sovereignty.

Product overview

IAMPS is the world's first industry association dedicated to representing microphysiological systems (MPS) providers across Europe. It is not a product company itself but a membership organization bringing together nine founding member companies: AlveoliX (AXBarrier-on-Chip), BiomimX (Organ-on-Chip), chiron (Re-plate™ and μMass™), Dynamic42 (DynamicOrgan® System), InSphero (3D spheroid/organoid models), MIMETAS (OrganoPlate® and OrganoReady®), NETRI (NeuroFluidics™ MEA and NaaS), React4Life (MIVO®), and TissUse (Multi-Organ-Chip). IAMPS serves as a unified industry voice to support the development, adoption and regulatory acceptance of MPS technologies, operating through three strategic pillars: Industrial Alignment, Regulatory Interface, and European Sovereignty.

Differentiator

Problem solved

Functional benefit

Products and services

• IAMPS Membership Membership-based association providing European MPS providers with a unified industry voice, coordinated regulatory engagement with global agencies (FDA, PMDA, MHRA, EMA), industrial alignment, standardization initiatives, and advocacy for European sovereignty in New Approach Methodologies (NAMs).
• Coordinated Regulatory Engagement Services Service offering unified industry-level dialogue with regulatory bodies (FDA, PMDA, MHRA, EMA) on validation, standardization, and methodology evaluation for New Approach Methodologies (NAMs), providing MPS providers with a one-stop interface for regulatory matters.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature9 records

Partnerships

Nine partnerships are on record, tiered core.

• AlveoliXcoreStrategic or Co-development Partner · 10 February 2026Swiss biotech company and founding member of IAMPS, specialized in advanced human-relevant in vitro models using AXBarrier-on-Chip technology for organ-on-chip applications including drug safety and efficacy testing.
• BiomimXcoreStrategic or Co-development Partner · 10 February 2026Italian pioneer in Organ-on-Chip technology developing Beating Organs-on-Chip platforms for pharmaceutical drug discovery and testing in cardiac, musculoskeletal, fibrotic, gastrointestinal and lung disorders.
• ChironcoreStrategic or Co-development Partner · 10 February 2026Netherlands-based company with Re-plate™ and μMass™ microfluidics platforms enabling predictive human-relevant data for arthritis and oncology applications using primary human cells.
• Dynamic42coreStrategic or Co-development Partner · 10 February 2026German spin-off from University Hospital Jena providing immunocompetent physiological organ-on-chip models including DynamicOrgan® System for preclinical drug evaluation in human models.
• InSpherocoreStrategic or Co-development Partner · 10 February 2026Swiss 3D in vitro model company with spheroid and organoid based platforms providing robustness, reliability, reproducibility and scalability for drug discovery modernization.
• MIMETAScoreStrategic or Co-development Partner · 10 February 2026Netherlands-based global leader in human-relevant disease models based on proprietary OrganoPlate® platform, with operations in Europe, Asia, and USA serving global top-50 pharmaceutical industry.
• NETRIcoreStrategic or Co-development Partner · 10 February 2026French Techbio start-up with Neuron-as-a-sensor suite (NaaS) featuring world-first compartmentalized electrophysiology platform (NeuroFluidics™ MEA) for pain quantification and neurotoxicity assessment.
• React4LifecoreStrategic or Co-development Partner · 10 February 2026Italian biotech company with MIVO® technology for organ-on-chip systems addressing drug testing, personalized medicine, immuno-oncology, dermocosmetics, and nutraceuticals applications.
• TissUsecoreStrategic or Co-development Partner · 10 February 2026German biotechnology company with Multi-Organ-Chip platform simulating multiple human organs for toxicity, ADME profiles and efficacy prediction, utilized in drug development, cosmetics, food and nutrition since 2012.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• ASCCT (American Society for Cellular and Computational Toxicology): ASCCT is a US-based scientific society focused on cellular and computational toxicology, including New Approach Methodologies and alternatives to animal testing. While scientific rather than industry-trade in nature, it overlaps thematically with IAMPS's NAMs regulatory adoption mission.

Regional players

• HollandBIO: HollandBIO is the Dutch biotech industry association representing companies active in human health, bio-based economy, and agri-food. Two IAMPS founding members (Chiron, MIMETAS) are Dutch, making it a closely aligned national biotech association peer.
• France Biotech: France Biotech is the French association of life sciences companies and their partners, supporting innovation in health, digital health, and biotech. NETRI, one of IAMPS's founding members, is headquartered in France, making this a directly relevant national association peer.
• BIO Deutschland: BIO Deutschland is the German biotechnology industry association representing SMEs and larger companies in the German biotech sector. Two IAMPS founding members (Dynamic42, TissUse) are headquartered in Germany, making it a directly comparable national biotech association.
• BIA (BioIndustry Association): BIA is the UK trade association for the life sciences and biotechnology industry, providing advocacy, networking, and policy engagement. It is comparable to IAMPS as a national biotech industry association, although it operates at national (UK) rather than European-MPS-specific scope.
• Swiss Biotech Association: Swiss Biotech Association represents Swiss biotech companies and engages with Swiss and European regulators. Two IAMPS founding members (AlveoliX, InSphero) are Swiss, making this a natural sub-regional counterpart and potential partner organization.
• Assobiotec: Assobiotec is the Italian Association for the Development of Biotechnology and represents biotech companies operating in Italy. Two IAMPS founding members (BiomimX, React4Life) are Italian, making Assobiotec a natural national-level peer organization.

Direct peers

• EuropaBio: EuropaBio is the European Association for Bioindustries, representing biotechnology companies and trade associations across Europe. It is the closest structural analog to IAMPS as a European biotech industry association with a regulatory advocacy mandate, although its scope is broader than MPS specifically.

Broad incumbents

• BIO (Biotechnology Innovation Organization): BIO is the largest US-based biotechnology industry association, providing regulatory advocacy, industry events, and policy engagement for biotech companies. It is comparable to IAMPS in function (industry association serving biotech) but operates at much broader scale and is not MPS-focused.
• EFPIA (European Federation of Pharmaceutical Industries and Associations): EFPIA represents the European pharmaceutical industry and engages with EU regulators and policymakers on drug development frameworks. While broader than IAMPS, it shares the same European regulatory-advocacy role and is a natural counterpart for IAMPS's regulatory interface mission.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/iampseu

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Industry Alliance for Microphysiological Systems